A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
Latest Information Update: 31 May 2025
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Tiragolumab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms IMbrave152; SKYSCRAPER-14
- Sponsors Roche
Most Recent Events
- 27 Feb 2025 Status changed from recruiting to active, no longer recruiting.
- 10 Aug 2023 Status changed from not yet recruiting to recruiting.
- 19 Jun 2023 New trial record